Anti-Human CD257 (BAFF) (Belimumab) - 100 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CD257, commonly referred to as the BAFF, plays a crucial role in regulating B-cell survival, maturation, and differentiation by interacting with specific receptors such as TACI, BCMA, and BAFFR1. Through these interactions, BAFF exerts anti-apoptotic effects that promotethe survival of B cells, making it a key factor in the pathogenesis of autoimmune diseasesand B-cell malignancies. Elevated levels of BAFF have been associated with conditions likesystemic lupus erythematosus (SLE) and rheumatoid arthritis, where overactive B-cellscontribute to disease progression. Targeting CD257/BAFF has emerged as a promisingtherapeutic strategy for managing such disorders, as it can disrupt the signaling pathwaysthat maintain abnormal B-cell activity1, 2. Belimumab, a monoclonal antibody, specifically inhibits BAFF (also known as BLyS). Byneutralizing BAFF, Belimumab reduces the survival and activity of B- cells, therebydampening the autoimmune response. It is primarily used to treat SLE and lupus nephritis, conditions characterized by excessive B-cell activation and inflammation3, 4.

≥ 5.0 mg/ml

BAFF is distributed throughout the body, with high expression in B celllineage cells 3 . It is found in various tissues, including the blood, lymphatic tissues, and bonemarrow.